VACH
Voyager Acquisition Corp./Cayman IslandsCompany Information
- Company Name
- Voyager Acquisition Corp./Cayman Islands
- CIK
- CIK0002006815
- Category
- <br>Emerging growth company
- Ticker: Exchange
- VACH: Nasdaq, VACHU: Nasdaq, VACHW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- VACH
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- —
- Institutional shares owned
- —
- Shares outstanding
- —
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-05-20
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||
| Cash | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | ||||||
Assets Current | ||||||||||||||
| Assets Current | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | ||||||
| Cash Equivalents At Carrying Value | 0 | - | - | - | - | - | - | - | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Deferred Offering Costs | - | - | 267 | 265 | 262 | - | - | 0 | ||||||
| Investments And Cash | 272 | 270 | - | - | - | 259 | - | - | ||||||
| Assets | 272 | 270 | 268 | 265 | 262 | 260 | 257 | 0 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||
| Accrued Liabilities Current | - | - | - | - | - | - | - | 0 | ||||||
Liabilities Current | ||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 275 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | - | - | - | - | - | - | - | 0 | ||||||
| Liabilities | 287 | 13 | 13 | 12 | 12 | 12 | 12 | - | ||||||
| Temporary Equity Value Excluding Additional Paid In Capital | 1 | 270 | - | - | - | 259 | - | - | ||||||
Stockholders Equity | ||||||||||||||
| Retained Earnings Accumulated Deficit | -15 | -13 | -12 | -12 | -12 | -11 | -11 | -0 | ||||||
| Stockholders Equity | -15 | -13 | -12 | -12 | -12 | -11 | -11 | -0 | ||||||
| Liabilities And Stockholders Equity | 272 | 270 | 268 | 265 | 262 | 260 | 257 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVoyager Acquisition Corp./Cayman Islands (VACH) — SEC Financial Statements & Analysis
Voyager Acquisition Corp./Cayman Islands (VACH) is a biological products, (no diagnostic substances) company, incorporated in E9. Voyager Acquisition Corp./Cayman Islands trades on Nasdaq as: VACH, VACHU, VACHW. Voyager Acquisition Corp./Cayman Islands (VACH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-20. Based on that filing, On profitability, Voyager Acquisition Corp./Cayman Islands posts a Return on Equity (ROE) of -49.96% and a Return on Assets (ROA) of 2.52%. Per share, it reports EPS of $0.34, diluted EPS of $0.34, free cash flow per share of $0.08, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 2.46% year-over-year and EPS growth of 29.77% year-over-year. On the balance sheet, it maintains a current ratio of 0.00x, a quick ratio of 0.00x, working capital of $-274.64M, a debt-to-equity ratio of -18.69x, a debt ratio of 1.05, free cash flow of $1.57M (TTM), and net debt of $-26.67K. Figures sourced from SEC EDGAR.
- EPS TTM
- $0.34
- ROE TTM
- -49.96%
- ROA TTM
- 2.52%
- Debt To Equity
- -18.69x
- Free Cash Flow TTM
- $1.57M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Voyager Acquisition Corp./Cayman Islands in?
Voyager Acquisition Corp./Cayman Islands (VACH) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does VACH trade on?
Voyager Acquisition Corp./Cayman Islands (VACH) trades on the Nasdaq.
Where is Voyager Acquisition Corp./Cayman Islands incorporated?
Voyager Acquisition Corp./Cayman Islands is incorporated in Cayman Islands.
When was Voyager Acquisition Corp./Cayman Islands (VACH)'s most recent SEC filing?
Voyager Acquisition Corp./Cayman Islands (VACH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-20.
What is VACH's EPS (earnings per share)?
Voyager Acquisition Corp./Cayman Islands (VACH)'s trailing twelve month EPS is $0.34 as of 2026-03-31.
What is VACH's ROE (return on equity)?
Voyager Acquisition Corp./Cayman Islands (VACH)'s trailing twelve month Return on Equity (ROE) is -49.96% as of 2026-03-31.
What is VACH's ROA (return on assets)?
Voyager Acquisition Corp./Cayman Islands (VACH)'s trailing twelve month Return on Assets (ROA) is 2.52% as of 2026-03-31.